CSafe Global recently expanded its passive packaging portfolio with the launch of the AcuTemp Plus Series of solutions designed to address the temperature-controlled shipping needs of commercial pharmaceuticals, clinical trials, and emerging cell and gene therapies. 
 
Temperature protection in the emerging Cell and Gene Therapy (CGT) space is further amplified due to the value and uniqueness of CGT products and the complicated supply chain. The new AcuTemp Plus Series has been developed to meet the evolving and increasing demand and customer expectations for temperature performance, solution quality, and system robustness required of packaging solutions to protect shipments of novel cell and gene therapies. 
  
The AcuTemp Plus Series of packaging solutions has been designed with high-performance ThermoCor Vacuum Insulated Panels (VIP) for precise, end-to-end control of internal payload temperatures. The new range is available in multiple size configurations and temperature profiles, along with different integrated track and trace options. Also, the AcuTemp Plus Series is supported with a fully managed, end-to-end service infrastructure leveraging CSafe’s retest and reuse program, REPAQ. 
 
“We are proud to expand our cold chain packaging offerings for the Cell and Gene Therapy market, and have focused and invested significantly in R&D to develop best-in-class solutions to meet the demanding product requirements for this emerging class of medication.” stated Patrick Schafer, chief executive officer of CSafe Global. “Test results of the new AcuTemp Plus Series have been very impressive with temperature performances outlasting other market available solutions by a large margin.”